Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study

K. Schmiegelow, E. Forestier, J. Kristinsson, S. Söderhäll, K. Vettenranta, Richard M Weinshilboum, F. Wesenberg

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Myelotoxicity during thiopurine therapy is enhanced in patients, who because of single nucleotide polymorphisms have decreased activity of the enzyme thiopurine methyltransferase (TPMT) and thus more thiopurine converted into 6-thioguanine nucleotides. Of 601 children with acute lymphoblastic leukemia (ALL) who were treated by the NOPHO ALL-92 protocol, 117 had TPMT genotype determined, whereas for 484 patients only erythrocyte TPMT activity was available. The latter were classified as heterozygous, if TPMT activity was <14IU/ml, or deficient (<1.0IU/ml). 526 patients had TPMT wild type, 73 were presumed heterozygous, and two were TPMT deficient. Risk of relapse was higher for the 526 TPMT wild type patients than for the remaining 75 patients (18 vs 7%, P = 0.03). In cox multivariate regression analysis, sex (male worse; P = 0.06), age (higher age worse, P = 0.02), and TPMT activity (wild type worse; P = 0.02) were related to risk of relapse. Despite a lower probability of relapse, patients in the low TPMT activity group did not have superior survival (P = 0.82), possibly because of an excess of secondary cancers among these 75 patients (P = 0.07). These data suggest that children with ALL and TPMT wild type might have their cure rate improved, if the pharmacokinetics/-dynamics of TPMT low-activity patients could be mimicked without a concurrent excessive risk of second cancers.

Original languageEnglish (US)
Pages (from-to)557-564
Number of pages8
JournalLeukemia
Volume23
Issue number3
DOIs
StatePublished - 2009

Fingerprint

thiopurine methyltransferase
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Second Primary Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia : Results from the NOPHO ALL-92 study. / Schmiegelow, K.; Forestier, E.; Kristinsson, J.; Söderhäll, S.; Vettenranta, K.; Weinshilboum, Richard M; Wesenberg, F.

In: Leukemia, Vol. 23, No. 3, 2009, p. 557-564.

Research output: Contribution to journalArticle

Schmiegelow, K. ; Forestier, E. ; Kristinsson, J. ; Söderhäll, S. ; Vettenranta, K. ; Weinshilboum, Richard M ; Wesenberg, F. / Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia : Results from the NOPHO ALL-92 study. In: Leukemia. 2009 ; Vol. 23, No. 3. pp. 557-564.
@article{527f59e177bc4dd883f146b7158db62c,
title = "Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study",
abstract = "Myelotoxicity during thiopurine therapy is enhanced in patients, who because of single nucleotide polymorphisms have decreased activity of the enzyme thiopurine methyltransferase (TPMT) and thus more thiopurine converted into 6-thioguanine nucleotides. Of 601 children with acute lymphoblastic leukemia (ALL) who were treated by the NOPHO ALL-92 protocol, 117 had TPMT genotype determined, whereas for 484 patients only erythrocyte TPMT activity was available. The latter were classified as heterozygous, if TPMT activity was <14IU/ml, or deficient (<1.0IU/ml). 526 patients had TPMT wild type, 73 were presumed heterozygous, and two were TPMT deficient. Risk of relapse was higher for the 526 TPMT wild type patients than for the remaining 75 patients (18 vs 7{\%}, P = 0.03). In cox multivariate regression analysis, sex (male worse; P = 0.06), age (higher age worse, P = 0.02), and TPMT activity (wild type worse; P = 0.02) were related to risk of relapse. Despite a lower probability of relapse, patients in the low TPMT activity group did not have superior survival (P = 0.82), possibly because of an excess of secondary cancers among these 75 patients (P = 0.07). These data suggest that children with ALL and TPMT wild type might have their cure rate improved, if the pharmacokinetics/-dynamics of TPMT low-activity patients could be mimicked without a concurrent excessive risk of second cancers.",
author = "K. Schmiegelow and E. Forestier and J. Kristinsson and S. S{\"o}derh{\"a}ll and K. Vettenranta and Weinshilboum, {Richard M} and F. Wesenberg",
year = "2009",
doi = "10.1038/leu.2008.316",
language = "English (US)",
volume = "23",
pages = "557--564",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia

T2 - Results from the NOPHO ALL-92 study

AU - Schmiegelow, K.

AU - Forestier, E.

AU - Kristinsson, J.

AU - Söderhäll, S.

AU - Vettenranta, K.

AU - Weinshilboum, Richard M

AU - Wesenberg, F.

PY - 2009

Y1 - 2009

N2 - Myelotoxicity during thiopurine therapy is enhanced in patients, who because of single nucleotide polymorphisms have decreased activity of the enzyme thiopurine methyltransferase (TPMT) and thus more thiopurine converted into 6-thioguanine nucleotides. Of 601 children with acute lymphoblastic leukemia (ALL) who were treated by the NOPHO ALL-92 protocol, 117 had TPMT genotype determined, whereas for 484 patients only erythrocyte TPMT activity was available. The latter were classified as heterozygous, if TPMT activity was <14IU/ml, or deficient (<1.0IU/ml). 526 patients had TPMT wild type, 73 were presumed heterozygous, and two were TPMT deficient. Risk of relapse was higher for the 526 TPMT wild type patients than for the remaining 75 patients (18 vs 7%, P = 0.03). In cox multivariate regression analysis, sex (male worse; P = 0.06), age (higher age worse, P = 0.02), and TPMT activity (wild type worse; P = 0.02) were related to risk of relapse. Despite a lower probability of relapse, patients in the low TPMT activity group did not have superior survival (P = 0.82), possibly because of an excess of secondary cancers among these 75 patients (P = 0.07). These data suggest that children with ALL and TPMT wild type might have their cure rate improved, if the pharmacokinetics/-dynamics of TPMT low-activity patients could be mimicked without a concurrent excessive risk of second cancers.

AB - Myelotoxicity during thiopurine therapy is enhanced in patients, who because of single nucleotide polymorphisms have decreased activity of the enzyme thiopurine methyltransferase (TPMT) and thus more thiopurine converted into 6-thioguanine nucleotides. Of 601 children with acute lymphoblastic leukemia (ALL) who were treated by the NOPHO ALL-92 protocol, 117 had TPMT genotype determined, whereas for 484 patients only erythrocyte TPMT activity was available. The latter were classified as heterozygous, if TPMT activity was <14IU/ml, or deficient (<1.0IU/ml). 526 patients had TPMT wild type, 73 were presumed heterozygous, and two were TPMT deficient. Risk of relapse was higher for the 526 TPMT wild type patients than for the remaining 75 patients (18 vs 7%, P = 0.03). In cox multivariate regression analysis, sex (male worse; P = 0.06), age (higher age worse, P = 0.02), and TPMT activity (wild type worse; P = 0.02) were related to risk of relapse. Despite a lower probability of relapse, patients in the low TPMT activity group did not have superior survival (P = 0.82), possibly because of an excess of secondary cancers among these 75 patients (P = 0.07). These data suggest that children with ALL and TPMT wild type might have their cure rate improved, if the pharmacokinetics/-dynamics of TPMT low-activity patients could be mimicked without a concurrent excessive risk of second cancers.

UR - http://www.scopus.com/inward/record.url?scp=62549091437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549091437&partnerID=8YFLogxK

U2 - 10.1038/leu.2008.316

DO - 10.1038/leu.2008.316

M3 - Article

C2 - 18987654

AN - SCOPUS:62549091437

VL - 23

SP - 557

EP - 564

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -